Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy

Jan Beyer-Westendorf; Franziska Michalski; Luise Tittl; Susann Hauswald-Dörschel; Sandra Marten

doi:10.1160/TH15-11-0902

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2016; 115(06): 1234-1236
DOI: 10.1160/TH15-11-0902

Letters to the Editor

Schattauer GmbH

Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy

Jan Beyer-Westendorf

¹Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany

,

Franziska Michalski

¹Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany

,

Luise Tittl

¹Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany

,

Susann Hauswald-Dörschel

¹Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany

,

Sandra Marten

¹Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany

References
1 Ferreira M, Barsam S, Patel JP. et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol. 2015 Epub ahead of print.
2 De Crem N, Peerlinck K, Vanassche T. et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015 Epub ahead of print.
3 Martinelli I, Lensing AW, Middeldorp S. et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2015 Epub ahead of print.
4 Beyer-Westendorf J, Gelbricht V, Forster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
5 Beyer-Westendorf J, Gelbricht V, Forster K. et al. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014 Epub ahead of print.
6 Beyer-Westendorf J, Forster K, Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
7 Beyer-Westendorf J, Ebertz F, Forster K. et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.
8 Michalski F, Tittl L, Werth S. et al. Selection, management, and outcome of vitamin K antagonisttreated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015; 114: 1076-1084.
9 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.